Advertisement
Screener

INSMED INC (INSM) Amortization of Intangible Assets

2.8 / 5 stars · 68/120 Roast Me

INSMED INC Amortization of Intangible Assets

INSMED INC (INSM) reported Amortization of Intangible Assets of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06

  • INSMED INC amortization of intangible assets for the quarter ending 2026-06-30 was $2.08M, a 64.77% increase year-over-year.
  • INSMED INC amortization of intangible assets for the quarter ending 2026-03-31 was $2.08M, a 64.77% increase year-over-year.
  • INSMED INC amortization of intangible assets for the quarter ending 2025-12-31 was $1.94M, a 53.37% increase year-over-year.
  • INSMED INC amortization of intangible assets for the quarter ending 2025-09-30 was $1.54M, a 21.77% increase year-over-year.
  • INSMED INC amortization of intangible assets for fiscal 2025 was $6.00M, a 18.78% increase from fiscal 2024.
  • INSMED INC amortization of intangible assets for fiscal 2024 was $5.05M, a 0.00% change from fiscal 2023.
  • INSMED INC amortization of intangible assets for fiscal 2023 was $5.05M, a 0.02% decline from fiscal 2022.
  • INSMED INC amortization of intangible assets for fiscal 2022 was $5.05M, a 0.02% increase from fiscal 2021.
Period endAmortization of Intangible Assets 3 monthAmortization of Intangible Assets 6 monthAmortization of Intangible Assets 9 monthAmortization of Intangible Assets 12 month
2026-06-30$2.08M
10-Q · filed 2026-08-06
$4.16M
10-Q · filed 2026-08-06
$6.10M
derived: sum of 3 quarters · filed 2026-08-06
$7.64M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$2.08M
10-Q · filed 2026-05-07
$4.02M
derived: sum of 2 quarters · filed 2026-05-07
$5.56M
derived: sum of 3 quarters · filed 2026-05-07
$6.82M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$1.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$3.48M
derived: sum of 2 quarters · filed 2026-02-19
$4.74M
derived: sum of 3 quarters · filed 2026-08-06
$6.00M
10-K · filed 2026-02-19
2025-09-30$1.54M
10-Q · filed 2025-10-30
$2.80M
derived: sum of 2 quarters · filed 2026-08-06
$4.06M
10-Q · filed 2025-10-30
$5.33M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$1.26M
10-Q · filed 2026-08-06
$2.53M
10-Q · filed 2026-08-06
$3.79M
derived: sum of 3 quarters · filed 2026-08-06
$5.05M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$1.26M
10-Q · filed 2026-05-07
$2.53M
derived: sum of 2 quarters · filed 2026-05-07
$3.79M
derived: sum of 3 quarters · filed 2026-05-07
$5.05M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$2.53M
derived: sum of 2 quarters · filed 2026-02-19
$3.79M
derived: sum of 3 quarters · filed 2026-02-19
$5.05M
10-K · filed 2026-02-19
2024-09-30$1.26M
10-Q · filed 2025-10-30
$2.53M
derived: sum of 2 quarters · filed 2025-10-30
$3.79M
10-Q · filed 2025-10-30
$5.05M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30$1.26M
10-Q · filed 2025-08-07
$2.53M
10-Q · filed 2025-08-07
$3.79M
derived: sum of 3 quarters · filed 2026-02-19
$5.05M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31$1.26M
10-Q · filed 2025-05-08
$2.53M
derived: sum of 2 quarters · filed 2026-02-19
$3.79M
derived: sum of 3 quarters · filed 2026-02-19
$5.05M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$2.53M
derived: sum of 2 quarters · filed 2026-02-19
$3.79M
derived: sum of 3 quarters · filed 2026-02-19
$5.05M
10-K · filed 2026-02-19
2023-09-30$1.26M
10-Q · filed 2024-10-31
$2.53M
derived: sum of 2 quarters · filed 2024-10-31
$3.79M
10-Q · filed 2024-10-31
$5.05M
derived: sum of 4 quarters · filed 2025-02-20
2023-06-30$1.26M
10-Q · filed 2024-08-08
$2.53M
10-Q · filed 2024-08-08
$3.79M
derived: sum of 3 quarters · filed 2025-02-20
$5.05M
derived: sum of 4 quarters · filed 2025-02-20
2023-03-31$1.26M
10-Q · filed 2024-05-09
$2.53M
derived: sum of 2 quarters · filed 2025-02-20
$3.79M
derived: sum of 3 quarters · filed 2025-02-20
$5.05M
derived: sum of 4 quarters · filed 2025-02-20
2022-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20
$2.53M
derived: sum of 2 quarters · filed 2025-02-20
$3.79M
derived: sum of 3 quarters · filed 2025-02-20
$5.05M
10-K · filed 2025-02-20
2022-09-30$1.26M
10-Q · filed 2023-10-26
$2.53M
derived: sum of 2 quarters · filed 2023-10-26
$3.79M
10-Q · filed 2023-10-26
$5.05M
derived: sum of 4 quarters · filed 2024-02-22
2022-06-30$1.26M
10-Q · filed 2023-08-03
$2.53M
10-Q · filed 2023-08-03
$3.79M
derived: sum of 3 quarters · filed 2024-02-22
$5.05M
derived: sum of 4 quarters · filed 2024-02-22
2022-03-31$1.26M
10-Q · filed 2023-05-04
$2.52M
derived: sum of 2 quarters · filed 2024-02-22
$3.79M
derived: sum of 3 quarters · filed 2024-02-22
$5.05M
derived: sum of 4 quarters · filed 2024-02-22
2021-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
$2.53M
derived: sum of 2 quarters · filed 2024-02-22
$3.79M
derived: sum of 3 quarters · filed 2024-02-22
$5.05M
10-K · filed 2024-02-22
2021-09-30$1.26M
10-Q · filed 2022-10-27
$2.53M
derived: sum of 2 quarters · filed 2022-10-27
$3.79M
10-Q · filed 2022-10-27
$5.05M
derived: sum of 4 quarters · filed 2023-02-23
2021-06-30$1.26M
10-Q · filed 2022-08-04
$2.53M
10-Q · filed 2022-08-04
$3.78M
derived: sum of 3 quarters · filed 2023-02-23
$5.03M
derived: sum of 4 quarters · filed 2023-02-23
2021-03-31$1.26M
10-Q · filed 2022-05-05
$2.52M
derived: sum of 2 quarters · filed 2023-02-23
$3.77M
derived: sum of 3 quarters · filed 2023-02-23
$5.02M
derived: sum of 4 quarters · filed 2023-02-23
2020-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23
$2.51M
derived: sum of 2 quarters · filed 2023-02-23
$3.75M
derived: sum of 3 quarters · filed 2023-02-23
$5.00M
10-K · filed 2023-02-23
2020-09-30$1.25M
10-Q · filed 2021-10-28
$2.50M
derived: sum of 2 quarters · filed 2021-10-28
$3.75M
10-Q · filed 2021-10-28
$4.99M
derived: sum of 4 quarters · filed 2022-02-17
2020-06-30$1.25M
10-Q · filed 2021-08-05
$2.50M
10-Q · filed 2021-08-05
$3.75M
derived: sum of 3 quarters · filed 2022-02-17
$4.99M
derived: sum of 4 quarters · filed 2022-02-17
2020-03-31$1.25M
10-Q · filed 2021-05-06
$2.50M
derived: sum of 2 quarters · filed 2022-02-17
$3.75M
derived: sum of 3 quarters · filed 2022-02-17
$4.99M
derived: sum of 4 quarters · filed 2022-02-17
2019-12-31$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17
$2.50M
derived: sum of 2 quarters · filed 2022-02-17
$3.75M
derived: sum of 3 quarters · filed 2022-02-17
$4.99M
10-K · filed 2022-02-17
2019-09-30$1.25M
10-Q · filed 2020-10-29
$2.50M
derived: sum of 2 quarters · filed 2020-10-29
$3.75M
10-Q · filed 2020-10-29
$4.99M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$1.25M
10-Q · filed 2020-08-06
$2.50M
10-Q · filed 2020-08-06
$3.75M
derived: sum of 3 quarters · filed 2021-02-25
$3.75M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$1.25M
10-Q · filed 2020-04-30
$2.50M
derived: sum of 2 quarters · filed 2021-02-25
$2.50M
derived: sum of 3 quarters · filed 2021-02-25
$2.50M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$1.25M
derived: sum of 2 quarters · filed 2021-02-25
$1.25M
derived: sum of 3 quarters · filed 2021-02-25
$1.25M
10-K · filed 2021-02-25
2018-09-30$0.00
10-Q · filed 2019-10-30
$0.00
derived: sum of 2 quarters · filed 2019-10-30
$0.00
10-Q · filed 2019-10-30
2018-06-30$0.00
10-Q · filed 2019-08-01
$0.00
10-Q · filed 2019-08-01
2018-03-31$0.00
10-Q · filed 2019-05-07
2017-12-31$0.00
10-K · filed 2020-02-25
2016-12-31$0.00
10-K · filed 2019-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10